To explore the application effect of endoscopic over-the-scope clip (OTSC) anastomosis clip hemostasis therapy in patients with acute non-variceal upper gastrointestinal bleeding (ANVUGIB).

A total of 302 patients with ANVUGIB admitted to our hospital from October 2023 to August 2025 were selected as the research subjects. They were randomly divided into the control group and the observation group, with 151 cases in each group. The control group received endoscopic metal titanium clip hemostasis, while the observation group received endoscopic OTSC anastomosis clip hemostasis therapy. The hemostasis effect, stress response, inflammatory indicators, and adverse reactions were compared between the two groups.

The hemostasis time of the observation group was (4.12±1.08) min, which was shorter than that of the control group [(10.33±2.61) min]. The immediate hemostasis rate was 98.01% (148/151), which was higher than that of the control group [90.07% (136/151)], and the rebleeding rate within 7 days was 1.32% (2/151), which was lower than that of the control group [6.62% (10/151)], and the differences were statistically significant (P<0.05). After treatment, the cortisol (Cor) of the observation group was (282.62±39.66) nmol/L, interleukin-6 (IL-6) was (18.12±3.25) pg/mL, tumor necrosis factor-α (TNF-α) was (22.46±4.81) pg/mL, and C-reactive protein (CRP) was (5.12±1.26) mg/L, which were lower than those of the control group [(308.96±45.18) nmol/L, (27.11±3.94) pg/mL, (31.05±5.78) pg/mL, and (8.45±1.44) mg/L], and the differences were statistically significant (P<0.05); the incidence of adverse reactions in the observation group was 2.65% (4/151), which was lower than that of the control group [7.95% (12/151)], and the difference was statistically significant (P<0.05).

Endoscopic OTSC anastomosis clip hemostasis therapy for ANVUGIB has a definite hemostatic effect, can relieve stress response, reduce inflammatory levels, and has good safety.